The Effect of Switching Therapy to Pegaptanib in Eyes with the Persistent Cases of Exudative Age-related Macular Degeneration

The Effect of Switching Therapy to Pegaptanib in Eyes with the Persistent Cases of Exudative Age-related Macular Degeneration - Pegaptanib for Persistent Cases of AMD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020334

Enrollment

Registered

2015-12-26

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Cases of Exudative Age-related Macular Degeneration

Interventions

intravitreal pegaptanib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Despite an initial good response to the IVR treatment, optical coherence tomography showed thickening of the macular exudate, and there was deterioration of the visual function.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
maintaining or improvement of visual acuity	—

Countries

Japan

Contacts

Public ContactChieko Shiragami

Kagawa University Faculty of Medicine Department of Ophthalmology

chappi@kms.ac.jp+81-87-891-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026